Podcasts about Variant

What makes a hero? Charlotte and Zack use Dave as an example to consider this age-old question. Also, we talk about the new Disney+ show, Wonder Man. Up Next: My Marvelous Year — 2013 pt. 7 Comic Title Issues Notes Uncanny X-Men #1 to #4 Bendis jumps from Avengers to X-Men Guardians of the Galaxy […] The post My Marvelous Year 2013 Variant C: Wonder Man TV Show Review! appeared first on Comic Book Herald.

Today I sit down with investigative reporter Benjamin Ryan, who was the only journalist present for the entirety of the historic Variant v. Einhorn trial — the first detransition malpractice lawsuit in the world to reach a jury verdict. Ben has been covering pediatric gender medicine for three years for outlets including the New York Times, NBC News, the New York Sun, and the Free Press, and he brings an extraordinary level of detail to this conversation.We dive into the case of Fox Variant, a young woman diagnosed with autism who underwent a double mastectomy at age 16 after her psychologist, Kenneth Einhorn, wrote a referral letter riddled with errors and omissions — including listing body dysmorphic disorder instead of gender dysphoria. We discuss how the jury found Einhorn 70% responsible and plastic surgeon Dr. Chin 30% responsible for a $2 million award, the devastating testimony from Fox's mother about being coerced with suicide threats, and the critical communication failures between the psychologist and surgeon. We also explore what this verdict means for the nearly 30 other detransition lawsuits currently pending, why WPATH's standards of care were largely sidelined in the trial, and the broader implications for the field of pediatric gender medicine. I also share my own perspective as a therapist who worked for a group practice later acquired by the same company that employed Einhorn.Benjamin Ryan is an independent reporter who has been covering pediatric gender medicine for the past three years, including on his Substack: benryan.substack.com. He writes for publications such as The New York Times, NBC News and The New York Sun and covered the detransitioner trial for The Free Press. Follow him @BenRyanWriter on X or BlueSky.BenRyan.netBenjamin's article in the Free Press, A Legal First That Could Change Gender Medicine[00:00:00] Start[00:00:54] Introducing Reporter Benjamin Ryan[00:09:38] Fox Variant's Background and Rapid Transition[00:18:35] Were WPATH Guidelines Actually on Trial?[00:25:30] Disturbing Revelations From Einhorn's Treatment[00:35:15] Changing the Body to Treat the Mind[00:46:41] The Joanna Olson-Kennedy Lawsuit[00:55:32] The Jury Verdict Question by Question[01:06:41] Einhorn's Visible Devastation in Court[01:13:04] Q&A: Technicality or Broader Indictment?[01:31:31] What If WPATH Were Followed Perfectly?ROGD REPAIR Course + Community gives concerned parents instant access to over 120 lessons providing the psychological insights and communication tools you need to get through to your kid. Now featuring 24/7 personalized AI support implementing the tools with RepairBot! Use code SOMETHERAPIST2026 to take 50% off your first month.PODCOURSES: use code SOMETHERAPIST at LisaMustard.com/PodCoursesTALK TO ME: book a meeting.PRODUCTION: Looking for your own podcast producer? Visit PodsByNick.com and mention my podcast for 20% off your initial services.SUPPORT THE SHOW: subscribe, like, comment, & share or donate.Watch NO WAY BACK: The Reality of Gender-Affirming Care. Use code SOMETHERAPIST to take 20% off your order.MUSIC: Thanks to Joey Pecoraro for our song, “Half Awake,” used with gratitude & permission. ALL OTHER LINKS HERE. To support this show, please leave a rating & review on Apple, Spotify, or wherever you get your podcasts. Subscribe, like, comment & share via my YouTube channel. Or recommend this to a friend!Learn more about Do No Harm.Take $200 off your EightSleep Pod Pro Cover with code SOMETHERAPIST at EightSleep.com.Take 20% off all superfood beverages with code SOMETHERAPIST at Organifi.Check out my shop for book recommendations + wellness products.Show notes & transcript provided with the help of SwellAI.Special thanks to Joey Pecoraro for our theme song, “Half Awake,” used with gratitude and permission.Watch NO WAY BACK: The Reality of Gender-Affirming Care (our medical ethics documentary, formerly known as Affirmation Generation). Stream the film or purchase a DVD. Use code SOMETHERAPIST to take 20% off your order. Follow us on X @2022affirmation or Instagram at @affirmationgeneration.Have a question for me? Looking to go deeper and discuss these ideas with other listeners? Join my Locals community! Members get to ask questions I will respond to in exclusive, members-only livestreams, post questions for upcoming guests to answer, plus other perks TBD. ★ Support this podcast on Patreon ★

Tesla has introduced a new variant of the Model Y in the US, but sadly it's not the Model Y L. At least not yet. Plus: Apple CarPlay is reportedly still on the way for Teslas, Consumer Reports gives the Model Y a major accolade, and more! If you enjoy the podcast and would like to support my efforts, please check out my Patreon at https://www.patreon.com/teslapodcast and consider a monthly or (10% discounted!) annual pledge. Every little bit helps, and you can support for just $5 per month. And there are stacking bonuses in it for you at each pledge level, like early access to each episode at the $5 tier and the weekly Lightning Round bonus mini-episode (AND the early access!) at the $10 tier! And NO ADS at every Patreon tier! Also, don't forget to leave a message on the Ride the Lightning hotline anytime with a question, comment, or discussion topic for next week's show! The toll-free number to call is 1-888-989-8752. INTERESTED IN A FLEXIBLE EXTENDED WARRANTY FOR YOUR TESLA? Be a part of the future of transportation with XCare, the first extended warranty designed & built exclusively for EV owners, by EV owners. Use the code Lightning to get $100 off their "One-time Payment" option! Go to www.xcelerateauto.com/xcare to find the extended warranty policy that's right for you and your Tesla. P.S. Get 15% off your first order of awesome aftermarket Tesla accessories at AbstractOcean.com by using the code RTLpodcast at checkout. Grab the SnapPlate front license plate bracket for any Tesla at https://everyamp.com/RTL/ (don't forget the coupon code RTL too!). Enhance your car with cool carbon-fiber upgrades from RPMTesla.com and use the promo code RTLPOD+ for 10% off your next purchase. And make your garage door foolproof with the Infinity Shield – get yours at infinity-shield.com and use the promo code RTL at checkout for a 10% discount.

Comunidad WhatsApp: https://whatsapp.com/channel/0029VaLm2ZU5vKAF3mcBdP2V¿Recuerdas el olor a Castrol TTS por la mañana? En este episodio #EP54 viajamos a la época dorada de los ciclomotores en España. Cuando tener 14 años significaba libertad, y tu mayor preocupación era si la moto pasaría la ITV con el Yasuni puesto o si griparías el Top Rosa camino al instituto.Analizamos la cultura de las 49cc que definió a una generación: desde los trucajes artesanales en las Vespino y Variant, hasta la revolución de las Yamaha Jog RR, Aerox y las marchas con las Derbi Senda y Rieju. Hablamos de mecánica de barrio, de huidas de la Guardia Civil y de por qué la ley de 2010 mató al ciclomotor.En este vídeo verás:

Der Audi F 103 – Die Geburtsstunde eines Automobil-Giganten So unscheinbar der Audi F103 auch daherkommt, so bedeutend war er für den Volkswagenkonzern und seine Tochter, die Audi AG. Ausgangspunkt war der DKW F102, der schon rein optisch seine Ahnenfunktion nicht verleugnen kann. Das Problem des DKW: Er war die letzte in West-Deutschland produzierte Limousine mit Zweitakt-Motor und stand entsprechend wie Blei in den Händlerräumen. Das Schicksal aber hielt für den F 102 einige Wendungen bereit, die ihm ein zweites Dasein sicherten. So spielte der Ingenieur und Motorenentwickler Ludwig Kraus eine entscheidende Rolle bei der Entwicklung hin zum ersten Audi. Kraus kam von Mercedes und hatte dort einen Vielstoffmotor für das Militär entwickelt, der aber nie gebaut wurde. Als dann Mercedes damals Auto-Union kaufte, ging eben jener Ludwig Kraus mit seinem Vielstoffmotor mit dem Code-Namen Mexiko zu Auto-Union und wurde dann kurzerhand mit der Marke an Volkswagen verkauft. Aus dem Vielstoffmotor wurde ein technisch interessanter Viertakter, der keinfach in den nnur wenig modifizierten DKW F 102 gebaut wurde. Noch eine kleine Änderung an den Heckleuchten und -zack- war der Audi F 103 geboren und mit ihm die gleichnamige Firma. Das war 1965. Und da es im Programm des zukünftigen Automobil-Giganten noch kein weiteres Modell gab, hieß der F-103 von nun an auch einfach nur „Audi“. Heute ist er ein gesuchter Klassiker, der noch dazu günstig zu haben ist. Das ist insbesondere deshalb verwunderlich, weil gieriger Rostfraß die meisten der fast 400.000 produzierten Autos vernichtet hat. Ron und Fredo sind sich ungewöhnlich einig: Sie finden den Audi hübsch und halten die Kombi-Ausführung Variant am begehrenswertesten, am besten als Super 90. Was das alles mit dem AMC Gremlin, Klebefolie und August Horch zu tun hat – das erfahrt ihr in diesem Podcast.

In this special episode, recorded live at the 2025 Genomics England Research Summit, host Adam Clatworthy is joined by parents, clinicians and researchers to explore the long, uncertain and often emotional journey to a genetic diagnosis. Together, they go behind the science to share what it means to live with uncertainty, how results like variants of uncertain significance (VUS) are experienced by families, and why communication and support matter just as much as genomic testing and research. The panel discuss the challenges families face when a diagnosis remains out of reach, the role of research in refining and revisiting results over time, and how collaboration between researchers, clinicians and participants could help shorten diagnostic journeys in the future. Joining Adam Clatworthy, Vice-Chair for the Participant Panel, on this episode are: Emma Baple – Clinical geneticist and Medical Director, South West Genomic Laboratory Hub  Jamie Ellingford – Lead genomic data scientist, Genomics England  Jo Wright – Member of the Participant Panel and Parent Representative for SWAN UK  Lisa Beaton - Member of the Participant Panel and Parent Representative for SWAN UK  Linked below are the episodes mentioned in the episode:  What is the diagnostic odyssey?  What is a Variant of Uncertain Significance?  Visit the Genomics England Research Summit website, to get your ticket to this years event. You can download the transcript, or read it below. Sharon: Hello, and welcome to Behind the Genes. My name is Sharon Jones and today we're bringing you a special episode recorded live from our Research Summit held in June this year. The episode features a panel conversation hosted by Adam Clatworthy, Vice-Chair of the Participant Panel. Our guests explore navigating the diagnostic odyssey, the often-complex journey to reaching a genetic diagnosis. If you'd like to know more about what the diagnostic odyssey is, check our bitesize explainer episode, ‘What is the Diagnostic Odyssey?' linked in the episode description. In today's episode you may hear our guests refer to ‘VUS' which stands for a variant of uncertain significance. This is when a genetic variant is identified, but its precise impact is not yet known. You can learn more about these in another one of our explainer episodes, “What is a Variant of Uncertain Significance?” And now over to Adam. -- Adam: Welcome, everyone, thanks for joining this session. I'm always really humbled by the lived experiences and the journeys behind the stories that we talk about at these conferences, so I'm really delighted to be hosting this panel session. It's taking us behind the science, it's really focusing on the people behind the data and the lived experiences of all the individuals and the families who are really navigating this system, trying to find answers and really aiming to get a diagnosis – that has to be the end goal. We know it's not the silver bullet, but it has to be the goal so that everyone can get that diagnosis and get that clarity and what this means for their medical care moving forwards.    So, today we're really going to aim to demystify what this diagnostic odyssey is, challenging the way researchers and clinicians often discuss long diagnostic journeys, and we'll really talk about the vital importance of research in improving diagnoses, discussing the challenges that limit the impact of emerging research for families on this odyssey and the opportunities for progress. So, we've got an amazing panel here. Rather than me trying to introduce you, I think it's great if you could just introduce yourselves, and Lisa, I'll start with you. Lisa: Hi, I'm Lisa Beaton and I am the parent of a child with an unknown, thought to be neuromuscular, disease. I joined the patient Participant Panel 2 years ago now and I'm also a Parent Representative for SWAN UK, which stands of Syndromes Without A Name. I have 4 children who have all come with unique and wonderful bits and pieces, but it's our daughter who's the most complicated. Adam:  Thank you. Over to you, Jo. Jo:  Hi, I'm Jo Wright, I am the parent of a child with an undiagnosed genetic condition.  So I've got an 11-year-old daughter. 100,000 Genomes gave us a VUS, which we're still trying to find the research for and sort of what I'll talk about in a bit.  And I've also got a younger daughter. I joined the Participant Panel just back in December. I'm also a Parent Rep for SWAN UK, so Lisa and I have known each other for quite a while through that. Adam:  Thank you, Jo.  And, Jamie, you're going to be covering both the research and the clinician side and you kind of wear 2 hats, so, yeah, over to you. Jamie:  Hi, everyone, so I'm Jamie Ellingford and, as Adam alluded to, I'm fortunate and I get to wear 2 hats. So, one of those hats is that I'm Lead Genomic Data Scientist for Rare Disease at Genomics England and so work as part of a really talented team of scientists and engineers to help develop our bioinformatic pipelines, so computational processes. I work as part of a team of scientists and software engineers to develop the computation pipelines that we apply at Genomics England as part of the National Health Service, so the Genomic Medicine Service that families get referred to and recruited to, and we try to develop and improve those. So that's one of my hats. And the second of those is I am a researcher, I'm an academic at the University of Manchester, and there I work really closely with some of the clinical teams in the North West to try and understand a little bit more about the functional impact of genomic variants on kind of how things happen in a cell. So, we can explore a little bit more about that but essentially, it's to provide a little bit more colour as to the impact that that genomic variant is having. Adam: Great, thank you, Jamie. Over to you, Emma. Emma: My name's Emma Baple, I'm an academic clinical geneticist in Exeter but I'm also the Medical Director of the South West genomic laboratory hub, so that's the Exeter and Bristol Genomics Laboratory. And I wear several other hats, including helping NHS England as the National Specialty Advisor for Genomics. Adam: Thank you all for being here. I think it's really important before we get into the questions just to ground ourselves in like those lived experiences that yourself and Jo and going through. So, Lisa, I'm going to start with you. The term ‘diagnostic odyssey' gets bandied around a lot, we hear about it so many times, but how does that reflect your experience that you've been through and what would you like researchers and clinicians to understand about this journey that you're on, essentially? Lisa: So I think ours is less an odyssey and more of a roller-coaster, and I say that because we sort of first started on a genetic journey, as it were, when my daughter was 9 weeks of age and she's now 16½ – the half's very important – and we still have no answers. And we've sort of come a bit backwards to this because when she was 6 months old Great Ormond Street Hospital felt very strongly that they knew exactly what was wrong with her and it was just a case of kind of confirmation by genetics. And then they sent off for a lot of different myasthenia panel genes, all of which came back negative, and so having been told, “Yes, it's definitely a myasthenia, we just need to know which one it is,” at 4 years of age that was removed and it was all of a sudden like, “Yeah, thanks, sorry.” And that was really hard actually because we felt we'd had somewhere to hang our hat and a cohort of people with very similar issues with their children, and then all of a sudden we were told, “No, no, that's not where you belong” and that was a really isolating experience. I can remember sort of saying to the neuromuscular team, “Well is it still neuromuscular in that case?” and there was a lot of shrugging of shoulders, and it just…  We felt like not only had we only just got on board the life raft, then we'd been chucked out, and we didn't even have a floaty. And in many ways I think I have made peace with the fact that we don't have a genetic diagnosis for our daughter but it doesn't get easier in that she has her own questions and my older children – one getting married in August who's already sort of said to me, you know, “Does this have implications for when we have children?”  And those are all questions I can't answer so that's really hard. Adam:  Thank you, Lisa. Yourself, Jo, how would you describe the odyssey that you're currently experiencing? Jo: So my daughter was about one when I started really noticing that she was having regressions. They were kind of there beforehand but, I really noticed them when she was one, and that's when I went to the GP and then got referred to the paediatrician. So initially we had genetic tests for things like Rett syndrome and Angelman syndrome, which they were all negative, and then we got referred on to the tertiary hospital and then went into 100,000 Genomes. So we enrolled in 100,000 Genomes at the beginning of 2017, and we got our results in April of 2020, so obviously that was quite a fraught time. Getting our results was probably not as you would want to do it because it was kind of over the phone and then a random letter. So, what I was told in that letter was that a variant of uncertain significance had been identified and they wanted to do further research to see if it might be more significant. So we were to be enrolled into another research project called Splicing and Disease, which wasn't active at the time because everything had been put on hold for COVID, but eventually we went into that. So, I didn't know what the gene was at that point, when I eventually got the form for going to get her bloods done…  So that went off and then that came back and the geneticist said, “That gives us some indication that it is significant.” So, since that point it's been trying to find more information and research to be able to make it a diagnosis. There have been 2 sort of key things that have happened towards that but we're still not there. So one of the things is that a research paper came out earlier this year so that's kind of a little bit more evidence, it's not going to give us a diagnosis but it kind of, you know, sits there. And the other thing is that my geneticist said, “Actually, yeah, it looks like it's an important change.”  That's as far as we've got. So we've still got work to do to make it a diagnosis or not.  Obviously if it is a diagnosis, it is still a one-of-a-kind diagnosis, so it doesn't give me a group to join or that kind of thing. But now I've got that research paper that I've read and read, and asked ChatGPT to verify that I've understood it right in some places, you know, with the faith that we put into ChatGPT (laughs), I've got a better understanding and I've got something now that I can look back on, the things that happened when my daughter was one, 2, 3, 4 and her development was all over the place and people thought that I was slightly crazy for the things I was saying, that “Actually, no, I can see what's happening.” So, it's like the picture's starting to come into focus but there's work to do. I haven't got a timeframe on that, I don't know when it's going to come together. And I always say that I'm a prolific stalker of the postman; ever since our first genetic tests you're just constantly waiting for the letters to drop through the door. So a diagnostic odyssey to me is just waiting for random events. Adam: I think what you've both kind of really clearly elaborated on is how you're the ones that are having to navigate this journey, you're the ones that are trying to piece this puzzle together, and the amount of time you're investing, all whilst navigating and looking after your child and trying to cope with the daily lived experience as well. And something you've both touched on that I'd love to draw out more is about how exactly was the information shared with you about the lack of diagnosis or the VUS or what's going on, because in our case you get this bit of paper through the post that has all these numbers and it's written in clinical speak and we had no conversation with the geneticist or the doctors. You see this bit of paper and you're reading it, scared for what the future will hold for your child, but I'd love to know like how were you communicated whilst all this is going on, how did you actually find out the next steps or any kind of future guidance. Lisa: So I think in our case we kept sort of going onto neuromuscular appointments, and I think for probably the first 5 years of my daughter's life I kind of had this very naïve thought that every time we turned up to an appointment it would be ‘the one' and then…   I think it would've been really helpful actually in those initial stages if they had said to us, “Actually, we don't know when this is going to happen, if it's even going to happen, you need to kind of prepare yourself for that.” It sounds fairly obvious to say but you don't know what you don't know. And in some ways we were getting genetic test results back for some really quite horrible things and they would tell us, “Oh it's good news, this mitochondrial disorder hasn't come up,” and so part of you is like, “Yay!” but then another part of you is thinking, “Well if it's not that what is it?” And we've very much kind of danced around and still don't really have an answer to whether it's life-limiting. We know it's potentially life-threatening and we have certain protocols, but even that is tricky. We live in North Yorkshire, and our local hospital are amazing. Every time we go in, if it's anything gastro-related, they say to me, “What's the protocol from Great Ormond Street?” and I say, “We don't have one” (laughs) and that always causes some fun. We try to stay out of hospitals as much as we absolutely can and do what we can at home but, equally, there's a point where, you know, we have to be guided by where we're going with her, with the path, and lots of phone calls backwards and forwards, and then is it going to be a transfer down to Great Ormond Street to manage it. And actually the way I found out that nothing had been found from 100,000 Genomes was in a passing conversation when we had been transferred down to Great Ormond Street and we'd been an inpatient for about 6 weeks and the geneticist said to me, “So obviously with you not having a diagnosis from the 100,000 Genomes…” and I said, “Sorry?  Sorry, what was that?  You've had the information back?”  And she said, “Well, yes, did nobody write to you?” and I said, “No, and clearly by my shock and surprise.” And she was a bit taken aback by that, but it happened yet again 2 years later (laughs) when she said, “Well you know everything's been reanalysed” and I said, “No.”  (Laughs)  And, so that's very much, it still feels an awful lot like I'm doing the heavy lifting because we're under lots of different teams and even when they're working at the same hospital they don't talk to each other. And I do understand that they're specialists within their own right, but nobody is really looking at my daughter holistically, and there are things that kind of interrelate across.    And at one of the talks I attended this morning they were talking about the importance of quality of life, and I think that is something that has to be so much more focused on because it's hard enough living without a diagnosis, but when you're living with a bunch of symptoms that, I think the best way I can describe it is at the moment we've got the spokes of the umbrella but we don't have the wrapper, and we don't know where we're going with it. We can't answer her questions, we can't even necessarily know that we're using the most effective treatments and therapies for her, and she's frustrated by that now, being 16, in her own right, as well as we are. And I'm panicking about the navigation towards Adult Services as well because at the minute at least we have a clinical lead in our amazing local paediatrician but of course once we hit and move into that we won't even have him and that's a really scary place to be, I think. Adam: Jo, is there anything you wanted to add on that in terms of how you've been communicated to whilst all this is going on? Jo: Yeah, so I think part of what makes it difficult is if you're across different hospitals because they're not necessarily going to see the same information. So obviously it was a bit of a different time when I got our results, but I got our results on a virtual appointment with a neurologist in one hospital, in the tertiary hospital, and because he could see the screen because it was the same hospital as genetics, and he said, “Oh you've got this” and then the letter came through later. When I had my next appointment with the neurologist in our primary hospital, or secondary care, whatever it's called, in that hospital, he hadn't seen that, so I'm telling him the results, which isn't ideal, but it happens quite a lot. What I think is quite significant to me is the reaction to that VUS.  I have to give it, the doctors that look after my daughter are brilliant, and I'm not criticising them in any way but their reaction to a VUS is “I'm so grateful for the persistence to get to a diagnosis.” Neurologists are a bit more like “Oh it's a VUS so it might be significant, it might be nothing.” Actually, as a patient, as in a parent, you actually want to know is it significant or not, “Do I look at it or not?” And, I mean, like I said, there were no research papers to look at before anyway until a few months ago so I didn't have anything to look at, but I didn't want to look at it either because you don't want to send yourself off down a path. But I think that collective sort of idea that once someone gets a VUS we need a pathway for it, “What do we do with it, what expectation do we set the patients up with and what is the pathway for actually researching further?” because this is where we really need the research. Adam:  Thank you, Jo. So, Emma, over to you in terms of how best do you think clinicians can actually support patients at navigating this odyssey and what's the difference between an initial diagnosis and a final diagnosis and how do you then communicate that effectively to the patients and their family?   Emma: So I think a key thing for me, and it's come up just now again, is that you need to remember as a doctor that the things you say at critical times in a patient's or parent's journeys they will remember – they'll remember it word for word even though you won't – and thinking about how to do that in the most sensitive, empathetic, calm, not rushed way is absolutely key.   And there are some difficulties with that when you're in a very high-pressure environment but it is absolutely crucial, that when you are communicating information about test results, when you're talking about doing the test in the first place, you're consenting the family, you're explaining what you're trying to do and those conditions, you balance how much information you give people.    So, you were talking earlier about “So you haven't got this diagnosis, you haven't got that diagnosis,” I often think it's…  We're often testing for numerous different conditions at the same time, I couldn't even list them all to the parents of the children or the patient that I'm testing. It's key to try and provide enough information without overwhelming people with so much information and information on specific conditions you are just thinking about as a potential.  Sometimes very low down your list actually but you can test for them.    Because people go home and they use the internet and they look things up and they get very, very worried about things. So, for me it's trying to provide bite-sized amounts of information, give it the time it deserves, and support people through that journey, tell them honestly what you think the chance of finding a diagnosis is. If you think it's unlikely or you think you know, sharing that information with family is helpful.   Around uncertainty, I find that a particular challenge. So, I think we've moved from a time when we used to, in this country, declare every variant we identified with an uncertain significance. Now, if we remember that we've all got 5 million variants in our genome, we've all got hundreds and hundreds… thousands and thousands, in fact, of variants of uncertain significance in our genetic code. And actually, unless you think a variant of uncertain significance genuinely does have a probability of being the cause of a child's or a patient's condition, sharing that information can be quite harmful to people.    We did a really interesting survey once when we were writing the guidelines for reporting variants of uncertain significance a few years ago. We asked the laboratories about their view of variants of uncertain significance and we asked the clinicians, and the scientists said, “We report variants of uncertain significance because the clinicians want them” and the clinicians said, “If the labs put the variant of uncertain significance on the report it must be important.” And of course, if you're a parent, if the doctor's told you the variant is a variant of uncertain significance of course you think it's important.    So, we should only be sharing that information, in my opinion, if it genuinely does have a high likelihood of being important and there are things that we can do. And taking people through that journey with you, with the degree of likelihood, the additional tests you need to do and explaining to them whether or not you think you will ever clarify that, is really, really key because it's very often that they become the diagnosis for the family.  Did I cover everything you think's important, both of you?  Lisa: I think the one thing I would say is that when you are patient- or parent-facing, the first time that you deliver that news to the parent… you may have delivered that piece of news multiple times and none of us sit there expecting you to kind of be overcome with emotion or anything like that but, in the same way that perhaps you would've had some nerves when, particularly if it was a diagnosis of something that was unpleasant, you know, to hold onto that kind of humanity and humility. Because for those patients and parents hearing that news, that is the only time they're ever hearing that, and the impact of that, and also, they're going on about with their day, you don't know what else they're doing, what they're juggling.    We're not asking you all to be responsible for kind of, you know, parcelling us up and whatnot but the way information is imparted to us is literally that thing we are all hanging our hats on, and when we're in this kind of uncertainty, from my personal experience I'm uncomfortable, I like to be able to plan, I'm a planner, I'm a researcher, I like to sort of look it up to the nth degree and that, and sitting in a place without any of that is, it's quite a difficult place to be. And it's not necessarily good news for those parents when a test comes back negative, because if it's not that then what is it, and that also leaves you feeling floundering and very isolated at times.  Adam: Yeah, and you touched upon the danger of like giving too much information or pushing families down a particular route, and then you have to pull them out of it when it's not that.   You talked about the experience you had, you felt like you'd found your home and then it's like, “Well, no, no, sorry, actually we don't think it's that.” And you've invested all of your time and your emotion into being part of that group and then you're kind of taken away again. So it's to the point where you have to be really sure before you then communicate to the families, and obviously in the meantime the families are like, “We just need to know something, we need to know,” and it's that real fine line, isn't it?    But, Jamie, over to you. Just thinking about the evolving nature of genomic diagnosis, what role does research play in refining or confirming a diagnosis over time?  Jamie: So it's really, really difficult actually to be able to kind of pinpoint one or 2 things that we could do as a community of researchers to help that journey, but perhaps I could reflect on a couple of things that I've seen happen over time which we think will improve things. And one of that's going back to the discussion that we've just had about how we classify genetic variants. And so, behind that kind of variant of uncertain significance there is a huge amount of effort and emotion from a scientist's side as well because I think many of the scientists, if not all, realise what impact that's going to have on the families.   And what we've tried to do as a community is to make sure that we are reproducible, and if you were to have your data analysed in the North West of England versus the South West that actually you'd come out with the same answer. And in order to do that we need guidance, we need recommendations, we need things that assist the scientists to actually classify those variants.  And so, what we have at the moment is a 5 point scale which ranges from benign to likely benign, variant of uncertain significance, unlikely pathogenic variant and pathogenic variant. It's objective as to how we classify a variant into one of those groups and so it's not just a gut feeling from a scientist, it's kind of recordable measurable evidence that they can provide to assist that classification.   So in many instances what that does is provide some uncertainty, as we've just heard, because it falls into that zone of variant of uncertain significance but what that also does is provide a framework in which we can generate more evidence to be able to classify it in one direction or another to become likely pathogenic or to become likely benign. And as a research community we're equipped with that understanding –– and not always with the tools but that's a developing area – to be able to do more about it.   What that doesn't mean is that if we generate that evidence that it can translate back into the clinic, and actually that's perhaps an area that we should discuss more. But kind of just generating that evidence isn't always enough and being able to have those routes to be able to translate back that into the hands of the clinicians, the clinical scientists, etc, is another challenge. Adam:  And how do you think we can drive progress in research to deliver these answers faster, to really try and shorten those diagnostic journeys, like what are the recommendations that you would say there? Jamie:  So being able to use the Genomics England data that's in the National Genomic Reference Library, as well as kind of other resources, has really transformed what we can do as researchers because it enables teams across the UK, across the world to work with data that otherwise they wouldn't be able to work with.   Behind that there's an infrastructure where if researchers find something which they think is of interest that can be reported back, it can be curated and analysed by teams at Genomics England and, where appropriate, kind of transferred to the clinical teams that have referred that family. And so having that pathway is great but there's still more that we can do about this. You know, it's reliant on things going through a very kind of fixed system and making sure that clinicians don't lose contact with families – you know, people move, they move locations, etc. And so, I think a lot of it is logistical and making sure that the right information can get to the right people, but it all falls under this kind of umbrella of being able to translate those research findings, where appropriate, into clinical reporting.   Adam:  Thank you. And, Emma, is there anything you would add in terms of like any key challenges that you think need to be overcome just to try and shorten the journeys as much as possible and find the answers to get a diagnosis?  Emma: I think trying to bridge that gap between some of the new technologies and new approaches that we've got that we can access in a research context and bringing those into diagnostics is a key area to try to reduce that diagnostic odyssey, so I really want to see the NHS continuing to support those sorts of initiatives.   We're very lucky, as Jamie said, the National Genomic Research Library has been fundamental for being able to reduce the diagnostic odyssey for large numbers of patients, not just in this country but around the world, and so trying to kind of look at how we might add additional data into the NGRL, use other research opportunities that we have in a more synergistic way with diagnostics I think is probably key to being able to do that.    We are very lucky in this country with the infrastructure that we've got and the fact that everything is so joined up. We're able to provide different opportunities in genomics for patients with rare conditions that aren't so available elsewhere in the world.  Adam: Great, thank you. I think we're it for time, so thank you very much to the panel. And I'd just say that if you do have any further questions for ourselves as participants then we're only too happy to pick those up. Thank you for lasting with us ‘til the end of the day and hope to see you soon.  -- Sharon: A huge thank you to our panel, Adam Clatworthy, Emma Baple, Jo Wright, Lisa Beaton and Jamie Ellingford, for sharing their insights and experiences. Each year at the summit, the Behind the Genes stage hosts podcast style conversations, bringing together researchers, clinicians and participants to discuss key topics in genomics.  If you're interested in attending a future Genomics England Research Summit, keep an eye out on our socials. If you'd like to hear more conversations like this, please like and subscribe to Behind the Genes on your favourite podcast app. Thank you for listening.    I've been your host, Sharon Jones. The podcast was edited by Bill Griffin at Ventoux Digital and produced by Deanna Barac.

Aquest dimecres està prevista una manifestació en contra de la Variant de les Preses i Olot, que comportarà afectacions al trànsit a la rotonda del túnel de Bracons. En parlem amb Moisès Mont de Salvem les Valls

Zack and Charlotte trade stories about what Dave means to them in this uplifting, tear-jerking Variant. Up Next: My Marvelous Year — 2013 pt. 5 Comic Title Issues Notes Infinity See reading order You’ll definitely want to follow the Infinity reading order because Hickman weaves between Infinity, Avengers and New Avengers. Mighty Avengers #1 to […] The post My Marvelous Year 2013 Variant B: Marvel and DC Crossover, Doomsday Teasers appeared first on Comic Book Herald.

A new MP3 sermon from Alpha and Omega Ministries is now available on SermonAudio with the following details: Title: Baptists for the Holy Roman Empire, the Variant at 1 Timothy 3:16 Subtitle: The Dividing Line 2026 Speaker: Dr. James White Broadcaster: Alpha and Omega Ministries Event: Podcast Date: 1/15/2026 Length: 67 min.

Lamont made his weekly check-in on their NewsMaker line and this time around got a call from Robert F. Kennedy Jr. Listen to The Lamont Show Monday through Friday, 6-10am, on 107.7 The Bone. For more of 107.7 The Bone go to: 1077thebone.com Connect with 107.7 The Bone on Facebook, Instagram, X, YouTube and TikTok. Connect with 107.7 The Bone on Apple, Spotify orSee omnystudio.com/listener for privacy information.

Lamont made his weekly check-in on their NewsMaker line and this time around got a call from Robert F. Kennedy Jr. Listen to The Lamont Show Monday through Friday, 6-10am, on 107.7 The Bone. For more of 107.7 The Bone go to: 1077thebone.com Connect with 107.7 The Bone on Facebook, Instagram, X, YouTube and TikTok. Connect with 107.7 The Bone on Apple, Spotify or Amazon Music.See omnystudio.com/listener for privacy information.

As promised, I looked over the "Sacralism on Steroids" graphic put out by the "New Christian Right" putting Donald Trump as Constantine (seriously) and noted the simplistic history that always accompanies these kinds of movements. Then we looked at the variant at 1 Timothy 3:16 as it was addressed by my upcoming debate opponent, Dr. Dustin Smith, in a recent podcast. Today's program has a fair amount of graphical information so audio only folks might be missing out on some things.

This podcast discusses the significance of variant histology in urothelial cancer, emphasizing the need for tailored treatment approaches based on histological features. Experts David Aggen, Tom Powles and Brian Rini explore various variant histologies, their implications for treatment, and the challenges in managing mixed histology tumors. The conversation highlights the importance of expert pathology reviews and the evolving landscape of neoadjuvant therapy in this field.

Was passiert, wenn Walker auf einmal Türen öffnen und Zäune hochklettern können? Was tut man, wenn die eigene Abfälligkeit auf Tonband aufgenommen und dann dem Volk vorgespielt wird? Und wie viele Charaktere aus TWD könntet ihr spontan unter Zeitdruck aufzählen? Wir besprechen heute The Walking Dead Staffel 11 Folge 17, 18, 19 & 20. Nächste Woche besprechen wir die LETZTEN 4 Folgen! Instagram: @aliciajoe und @cashisclay_attitude Learn more about your ad choices. Visit megaphone.fm/adchoices

De wereld werd afgelopen week geconfronteerd met de vijandige overname van Venezuela door de VS – Trump had opdracht gegeven om president Maduro af te zetten en gevangen te nemen, om zelf de besturing van Venezuela over te nemen. Karin en Marischka vertalen deze ontwikkeling in deze eerste podcast van 2026 naar wat er in organisaties op regelmatige basis gebeurt: de vijandige overname van een organisatie door een andere. En hoewel zo'n overname niet met bommen en granaten plaatsvindt en de CEO van de organisatie niet gevangen wordt genomen, is het wel een drastische schok die door de organisatie loopt. En wat doe je dan als manager, leidinggevende en/of stafprofessional in zowel de overnemende als de overgenomen partij?

It's that time of year again: coughs, sniffles and a whole lot of people feeling achy and run down. Chicago is among several US cities experiencing a surge in influenza cases, and a new strain of influenza called subclade K or “super K” is partly to blame. On today's In the Loop, we talk with experts about how to protect yourself and your family from the flu. Our panel today: Dr. Brian Borah, medical director for the Vaccine Preventable Disease Surveillance Program at the Chicago Department of Public Health; and Dr. Nicholas Cozzi, emergency physician at Rush. For a full archive of In the Loop interviews, head over to wbez.org/intheloop.

AP correspondent Ed Donahue reports the number of flu cases is rising rapidly across the country.

Another year and a few dozen comic reads under Josh and Travis's belt. Join the boys as they look back at their favorite reads, artists, heroes, and villains from their 2025 comic stack!

Dave keeps Zack and Charlotte laughing and laughing, and they praise him for an hour straight! Today’s episode is sponsored by GIT Collections, offering complete digital comics collections of the full histories of characters like Spider-Man, the Fantastic Four, Captain America, Iron Man and X-Men. Visit today and use promo code MMY at checkout for […] The post My Marvelous Year: 2025 Holiday Variant! Best of the Year! Kidney Stones! Zack Finally Snaps! appeared first on Comic Book Herald.

Dr. Santina Wheat, Program Director, McGaw Northwestern Family Medicine Residency Northwestern Medicine, Delnor Hospital, joins Dean Richards for this week's health update. They talk about the “super flu” variant spreading across the US and the steps people can take to avoid sickness.

Chief Medical Officer of Northwestern Medicine's Northwest region of hospitals Dr. Irfan Hafiz joins Wendy Snyder (in for Bob Sirott) to talk about a rise in flu cases, the benefits of cutting saturated fats our of your diet, a study that links cheese to a lower dementia risk, and how many hours of sleep we […]

A new version of the common flu is spreading globally, and health officials are monitoring this evolving strain of influenza A which has been increasingly detected worldwide. In other news, It's official: McKinney National Airport has its first airline. Avelo Airlines, the Houston-based budget carrier, signed a five-year use and lease agreement, the airport said Tuesday evening; Dallas Mavericks owner and casino magnate Miriam Adelson urged President Donald Trump to run for a third term in 2028; nd Romeo Santos and Prince Royce will perform together for the first time in Dallas next spring as part of their “Mejor Tarde Que Nunca” tour. In Dallas, they will perform on Saturday, May 9, at American Airlines Center. Tickets go on sale this Friday, Dec. 19. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Glenn Wortmann, Medical Director of Infection Prevention at the MedStar Institute of Quality and Safety, joins WAMU to discuss how to prepare for the upcoming flu season, which he and other medical experts warn will be a "tough one."

#top .av-special-heading.av-gs9o3p-a443d9b06c7f20b971d6f355b070045a{ padding-bottom:10px; } body .av-special-heading.av-gs9o3p-a443d9b06c7f20b971d6f355b070045a .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-gs9o3p-a443d9b06c7f20b971d6f355b070045a .av-subheading{ font-size:15px; } Through My Bible Yr 02 – December 17Daniel 11:2-20 LISTEN HERE Through My Bible – December 17 Daniel 11:2-20 (EHV) https://wels2.blob.core.windows.net/tmb-ehv/02-1217db.mp3 See series: Through My Bible Daniel 11 The Messenger Reveals Future Battles [1] Xerxes of Persia [2] 2 Now I will tell you the truth: Look, three more kings will arise for Persia. Then the fourth one will gain great riches, more than anyone else. As he becomes strong through his riches, he will stir everyone up against the kingdom of Greece. Alexander the Great [3] 3 A warrior king will arise. He will rule a great dominion and will do as he pleases. 4 But as he rises, his kingdom will be broken and be divided to the four winds of heaven, but it will not be passed on to his descendants. It will not be ruled with the same ruling power with which he ruled, because his kingdom will be uprooted and given to others besides these. The Ptolemies Versus the Seleucids [4] 5 The King of the South will become strong, but one of his commanders will become stronger than he and rule a dominion greater than his. [5] 6 After some years, they will make an alliance. The daughter of the King of the South will come to the King of the North and make a fair agreement. However, she will not keep the strength of her arm, and he and his arm [6] will not endure. She will be given up—she and those who brought her, the one who fathered her, [7] and the one who strengthened her during these times. [8] 7 But one who is a branch from her root will arise in his place. [9] He will come against the army and come into the fortress of the King of the North. He will make war with them and win. 8 He will also take their gods captive to Egypt with their cast images and with their valuable silver and gold vessels. For some years he will leave the King of the North alone. 9 But the King of the North will come into the kingdom of the King of the South. Then he will return to his own land. 10 His sons [10] will stir themselves up and will gather a huge force of many armies, which will keep coming like an overflowing flood. They will stir themselves up again as far as his fortress. [11] 11 The King of the South will be enraged. He will go out and fight with the King of the North. The King of the North will raise up a great army, but the army will be handed over to the King of the South. 12 When the King of the North's army is swept away, and the King of the South becomes arrogant, though he will cause tens of thousands to fall, he will not win. [12] Antiochus the Great 13 The King of the North will again raise an army, which will be greater than the first army, and after some years he will keep coming with a great army and many supplies. 14 In those times, many will rise up against the King of the South. Violent men from your own people will lift themselves up in fulfillment of this vision, but they will fail. 15 The King of the North will come and build siege works and capture a fortified city. The forces of the south will not stand, not even its best troops, because they will have no strength to stand. 16 The one who comes against him [13] will do as he pleases, and no one will stand in his way. He will stand in the beautiful land, [14] and it will be completely in his power. 17 He will be determined to come with the power of his entire kingdom and to bring a treaty with him, which he will enforce. He will give his daughter to the King of the South in marriage in order to destroy the southern kingdom. But his plan will not succeed or turn out to his advantage. 18 He will focus his attack on the coastlands and capture many. However, a commander will put an end to his insolence. Moreover, he will make him pay for his insolence. 19 Then the King of the North will turn his face toward the fortresses of his land. He will stumble and fall and not be found. [15] 20 Then one will arise in his place who will send an oppressive tax collector for the glory of his kingdom. However, in a few days he will be broken, but not in anger or battle. Footnotes Daniel 11:2 This prophecy, which continues into chapter 12, extends from Daniel's time till the end of the world. Understanding this chapter requires considerable knowledge of history, so the EHV includes more footnotes here than it usually does. For more information, consult commentaries and study Bibles. Daniel 11:2 Esther's husband Xerxes led a huge expedition against Greece that ended in failure in 480 bc. Daniel 11:3 Alexander of Macedon very quickly built up a great empire that stretched from Greece to India, about 330 years before Christ. Daniel 11:5 This is both one of the most amazing prophecies and one of the most difficult. Daniel, who lived in the 6th century bc, foretells in great detail events that happen from about 330 bc to 150 bc. The Ptolemies of Egypt and the Seleucids of Syria were two of the dynasties that succeeded Alexander. The Jews got caught in the middle of the conflict between them, and this led to a great persecution of the Jews. Consult commentaries and study Bibles for more details on this very complicated history. Daniel 11:5 The King of the South is Ptolemy of Egypt and his successors. The King of the North is Seleucus, a subordinate of Ptolemy who gained power in Syria, and his successors. Daniel 11:6 Variant seed, that is, descendant. The words for arm and seed look very much alike in Hebrew. Daniel 11:6 Variant her child Daniel 11:6 The kings are Ptolemy II and Antiochus II. The daughter of Ptolemy is Bernice, who was married to Antiochus. Antiochus eventually divorced Bernice and remarried his former wife Laodice, who then poisoned Antiochus, killed Bernice, and installed her own son as Seleucus II. Daniel 11:7 Bernice's brother, Ptolemy III, warred against Seleucus II. Daniel 11:10 The sons of Seleucus II were Seleucus III and Antiochus III the Great. They fought against the Ptolemies. Daniel 11:10 The line of thought in this verse is difficult to follow. Daniel 11:12 This King of the South is Ptolemy IV. Daniel 11:16 That is, the King of the North, who comes against the King of the South Daniel 11:16 That is, Israel Daniel 11:19 Antiochus the Great had success against both Egypt and Greece, but his plans were frustrated by the intervention of the Romans. It was at this time that Israel, which was between Syria and Egypt, got caught up in the conflict. #top .hr.hr-invisible.av-aocsdx-89cb4ca21532423cf697fc393b6fcee0{ height:10px; } The Holy Bible, Evangelical Heritage Version®, EHV®, © 2019 Wartburg Project, Inc. All rights reserved. #top .hr.hr-invisible.av-4vzadh-3f04b370105df1fd314a2a9d83e55b26{ height:50px; } Share this entryShare on FacebookShare on LinkedInShare by MailLink to FlickrLink to InstagramLink to Vimeo

Possible exploit variant for CVE-2024-9042 (Kubernetes OS Command Injection) We observed HTTP requests with our honeypot that may be indicative of a new version of an exploit against an older vulnerability. Help us figure out what is going on. https://isc.sans.edu/diary/Possible%20exploit%20variant%20for%20CVE-2024-9042%20%28Kubernetes%20OS%20Command%20Injection%29/32554 React2Shell: Technical Deep-Dive & In-the-Wild Exploitation of CVE-2025-55182 Wiz has a writeup with more background on the React2Shell vulnerability and current attacks https://www.wiz.io/blog/nextjs-cve-2025-55182-react2shell-deep-dive Notepad++ Update Hijacking Notepad++ s vulnerable update process was exploited https://notepad-plus-plus.org/news/v889-released/ New macOS PackageKit Privilege Escalation A PoC was released for a new privilege escalation vulnerability in macOS. Currently, there is no patch. https://khronokernel.com/macos/2024/06/03/CVE-2024-27822.html

You are listening to a presentation given at the 2025Michigan Conference Cedar Lake Campmeeting. We pray you will be blessed!

This week, we went live with Alana Levin from Variant Fund to discuss Variant's 2025 Crypto Trends Report, regulatory progress, stablecoin proliferation, DEX growth, wallet UX evolution, the future of global digital currencies, and more. Thanks for tuning in! As always, remember this podcast is for informational purposes only, and any views expressed by anyone on the show are solely their opinions, not financial advice. -- Resources The 2025 Crypto Trends Report: https://x.com/AlanaDLevin/status/1990804860027965727?s=20 -- Follow Blockworks Research: https://x.com/blockworksres Follow Variant Fund: https://x.com/variantfund Follow Alana: https://x.com/AlanaDLevin Follow Danny: https://x.com/defi_kay_ Follow Boccaccio: https://x.com/salveboccaccio -- Katana directs chain revenue back to DeFi users for consistently higher yields. It starts with VaultBridge, which turns bridged assets into yield streams that back a perpetually funded real yield, boosting rewards for DeFi users. Katana is pioneering Productive TVL, assets actually being used in DeFi and reinforces this with Chain-owned Liquidity, permanent liquidity the chain controls. Stop sleeping on your bags: https://app.katana.network/?utm_source=BW-Pod -- Uniswap's Trading API offers plug-and-play access to deep onchain and off-chain liquidity, delivering enterprise-grade crypto trading without the complexity - from one of the most trusted teams in DeFi.  Click to get started with seamless, scalable access to Uniswap's powerful onchain trading infrastructure. https://hub.uniswap.org/?utm_source=blockworks&utm_medium=podcast&utm_campaign=ww_web_bw_awa_trading-api_20251117_podcast_clicks -- Subscribe on YouTube: https://bit.ly/3foDS38 Subscribe on Apple: https://apple.co/3SNhUEt Subscribe on Spotify: https://spoti.fi/3NlP1hA Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ -- Timestamps: (0:00) Introduction (2:11) Market Outlook (8:31) The 2025 Crypto Trends Report (12:42) Overview of Variant Fund (15:35) Katana Ad (16:05) Potential Regulatory Risk (18:14) Crypto's Top Assets (22:24) New Crypto Assets (24:40) DEX Market Share Growth (31:14) Katana Ad (31:46) Improving Wallet UX (35:47) Stablecoin Fragmentation (46:28) Uniswap Ad (47:14) Productizing Stablecoins (52:57) Stablecoins Impact on USD Dominance (58:27) Closing Comments -- Check out Blockworks Research today! Research, data, governance, tokenomics, and models – now, all in one place Blockworks Research: https://www.blockworksresearch.com/ Free Daily Newsletter: https://blockworks.co/newsletter -- Disclaimer: Nothing said on 0xResearch is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Boccaccio, Danny, and our guests may hold positions in the companies, funds, or projects discussed.

Zack, Dave, and Charlotte talk about what we’d most like to see from Hickman’s career in the future, and bemoan our favorite tv shows cancelled too soon. Up Next: My Marvelous Year — 2012 pt. 10 X-Men Legacy #1 to #3 Marvel NOW sample platter FF #1 to #2 Avengers #1 to #3 Punisher Max […] The post My Marvelous Year 2012 Variant E: Worst TV Show Endings, and Jonathan Hickman’s Future Plans appeared first on Comic Book Herald.

It's a season finale! It's time to rank The Life of a Showgirl for real this time, none of this 'listen once and rank it', we have studied, we have debated, and now, these are our final rankings. Hosted on Acast. See acast.com/privacy for more information.

Dr. Jim Adams, Chief Medical Officer at Northwestern Medicine, joins Lisa Dent to discuss various health topics: A new heart disease calculator that gives a thirty-year risk factor, a flu variant from Japan, and hand foot and mouth disease on the rise

Prezident Petr Pavel nadále jedná s Andrejem Babišem o jeho střetu zájmů. Více než měsíc po volbách stále není jasné, jak Babiš veřejnosti svůj střet zájmů vysvětlí, jak po něm požaduje Pavel. „Indicie zatím naznačují, že se chystá nějaké nové řešení jako například slepý svěřenský fond,“ říká v rozhovoru s Tomášem Pancířem ústavní právník Ondřej Preuss.Všechny díly podcastu Dvacet minut Radiožurnálu můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Firas is joined by Northern Variant for an in-depth conversation on how we can fix Britain what's gone wrong, what needs to change, and what the future could look like if we get it right.

This is it, the final track-by-track before we finally figure out our final rankings.So could any of these be our faves? Not long until we find out! Hosted on Acast. See acast.com/privacy for more information.

This week, one of the audio editing tools we use suggested a synopsis to me that said this episode was about the liberation that freeform jazz provides... WHAT? My garauntee to you is that our episode descriptions will remain written by the same idiots talking on the podcast. In this episode we talk about eating habits, James Gunn movie updates, Felix Variants, and the DC/Marvel digital crossovers! Our comics are TMNT v Godzilla, Youngblood, American Caper, & Thor/Shazam!

-Get All Episodes Ad-Free Plus Exclusive & Early Access To Episodes On https://www.patreon.com/GeekVerse-When You Subscribe To Our Patreon You Help Us Grow The Podcast and Create New Content Guest On Shows, Pick Films For Us To Review, Send Topics & More!-GeekVerse.ca is where you can find all the info on the show and where you can find it! -Come Chat With The Hosts, Join Our Discord! https://discord.gg/R5dY4CwTBecome a supporter of this podcast: https://www.spreaker.com/podcast/geekverse-podcast--4201268/support.

Welcome to episode 13 of season 3, and it could be one of our longest breakdowns of tracks ever, especially as it appears we have a lot to say about 2 of these songs... Hosted on Acast. See acast.com/privacy for more information.

On this episode of THE GEEK BUDDIES, John Rocha and Michael Vogel discuss the rumors that Doctor Doom is a Tony Stark variant or if Tony Stark was a Doom variant. They also discuss The Mummy franchise returning with Brendan Fraser and Rachel Weisz, a Miss Piggy movie in development with Jennifer Lawrence and Emma Stone producing and Cole Escola writing it and the Variety article of Paramount's David Ellison highlighting his approach to rebooting Star Trek from scratch. Remember to Like and Share this episode on your social media and to Subscribe to The Outlaw Nation YouTube channel below. #marvel #avengers #startrek #disney #MCU #tonystark #robertdowneyjr #thegeekbuddies ____________________________________________________________________________________ Chapters: 0:00 Intro and Rundown 1:55 The Mummy Franchise Returning with Brendan Fraser and Rachel Weisz 12:32 Jennifer Lawrence and Emma Stone Teaming Up for Miss Piggy Movie 20:21 Paramount Rebooting Star Trek Completely 34:22 Is Doctor Doom a Tony Stark Variant or Was Tony Stark a Doom Variant FOLLOW THE GEEK BUDDIES: Twitter: https://twitter.com/Geek_Buddies Follow John Rocha: https://twitter.com/TheRochaSays​​​​​ Follow Michael Vogel: https://twitter.com/mktoon Follow Shannon McClung: https://twitter.com/Shannon_McClung Instagram: https://www.instagram.com/the_geek_bu... Learn more about your ad choices. Visit megaphone.fm/adchoices

Dave and Zack have a wide-ranging discussion about the best Spider-Man stories, sports podcasts, beat-em-up arcade games, the joys of powerwashing, and Zack’s gamer shame. Up Next: My Marvelous Year — 2012 pt. 8 Amazing Spider-Man #682 to #687, #698-#700 Ends of the Earth, big ol’ milestone Venom #16 to #22 Remender run on the […] The post My Marvelous Year 2012 Variant D: Best Spider-Man stories & Gamer Shame appeared first on Comic Book Herald.

Welcome to Variant 2, and as you can tell from the length of the episode, we have had many thoughts about these three tracks.But don't skip anything, it's all VERY important. Hosted on Acast. See acast.com/privacy for more information.

Oh, hey.Did you know Taylor Swift released a new song? Didn't think so.Well, she has! So, it's time to begin our long journey through every single song and deeply analyse every single little bit.We begin with Fate of Ophelia, Elizabeth Taylor & Opalite!See ya next week x Hosted on Acast. See acast.com/privacy for more information.

webctrl.cgi/Blue Angel Software Suite Exploit Attempts. Maybe CVE-2025-34033 Variant? Our honeypots detected attacks that appear to exploit CVE-2025-34033 or a similar vulnerability in the Blue Angle Software Suite. https://isc.sans.edu/diary/webctrlcgiBlue+Angel+Software+Suite+Exploit+Attempts+Maybe+CVE202534033+Variant/32410 Oracle Critical Patch Update Oracle released its quarterly critical patch update. The update includes patches for 374 vulnerabilities across all of Oracle s products. There are nine more patches for Oracle s e-Business Suite. https://www.oracle.com/security-alerts/cpuoct2025.html#AppendixEBS Rust TAR Library Vulnerability A vulnerability in the popular, but no longer maintained, async-tar vulnerability could lead to arbitrary code execution https://edera.dev/stories/tarmageddon

Limb-girdle muscular dystrophies (LGMDs) encompass a group of genetically heterogeneous skeletal muscle disorders. There has been an explosion of newly identified LGMD subtypes in the past decade, and results from preclinical studies and early-stage clinical trials of genetic therapies are promising for future disease-specific treatments. In this episode, Gordon Smith, MD, FAAN, speaks with Teerin Liewluck, MD, FAAN, FANA, author of the article “Limb-Girdle Muscular Dystrophies” in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Liewluck is a professor of neurology at the Division of Neuromuscular Medicine and Muscle Pathology Laboratory at Mayo Clinic College of Medicine in Rochester, Minnesota. Additional Resources Read the article: Limb-Girdle Muscular Dystrophies Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Guest: @TLiewluck Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Smith: This is Dr Gordon Smith with Continuum Audio. Today I'm interviewing Dr Teerin Liewluck, a good friend of mine at the Mayo Clinic, about his article on the limb girdle muscular dystrophies. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders, a topic that is near and dear to my heart. Teerin, welcome to the podcast, and maybe you can introduce yourself to our listeners. Dr Liewluck: Thank you very much, Gordon, and I want to say hi to all the Continuum fans. So, I'm Dr Teerin Liewluck, I'm the professor of neurology at Mayo Clinic in Rochester, Minnesota. So, my practice focus on all aspects of muscle diseases, both acquired and genetic myopathies. Glad to be here. Dr Smith: I just had the great pleasure of seeing you at a seminar in Houston where you talked about this topic. And so, I'm really primed for this conversation, which I'm very excited about. I find this topic a little hard, and I'm hoping I can learn more from you. And I wonder if, as we get started, recognizing many of our listeners are not in practices focused purely on muscle disease, maybe you can provide some context about why this is important for folks doing general neurology or even general neuromuscular medicine? Why do they need to know about this? Dr Liewluck: Yes, certainly. So, I would say limb girdle muscular dystrophy probably the most complex category of subgroup of muscle diseases because, by itself, it includes thirty-four different subtypes, and the number's still expanding. So, each subtype is very rare. But if you group together, it really have significant number of patients, and these patients present with proximal weakness, very high CK, and these are common patients that can show up in the neurology clinic. So, I think it's very important even for general neurologists to pick up what subtle clues that may lead to the diagnosis because if we are able to provide correct diagnosis for the patients, that's very important for patient management. Dr Smith: So, I wonder if maybe we can talk a little bit about the phenotype, Terran. I mean, your article does a great job of going over the great diversity. And you know, I think many of us here, you know, limb girdle muscular dystrophy and we think of limb girdle weakness, but the phenotypic spectrum is bananas, right? Rhabdomyolysis, limb girdle distal myopathy. I mean, when should our listeners suspect LGMD? Dr Liewluck: Yes, I think by the definition to all the LGMD patients will have limb girdle of proximal weakness and very high CK. So, these are common phenotypes among thirty-four different subtypes. But if it did take into details, they have some subtle differences. In the article, what I try to simplify all these different subtypes that we can categorize at least half of them into three main group that each group the underlying defect sharing among those subtypes and also translate into similar muscles and extra muscular manifestations. You will learn that some of the limb girdle muscular dystrophy may present with rhabdomyolysis. And we typically think of this as metabolic myopathies. But if you have a rhabdomyolysis patient, the CK remain elevated even after the acute episode, that's the key that we need to think this could be LGMD. That's for an example. Dr Smith: So, I wonder if maybe we can start there. I was going to go in a different direction, but this is a good transition. It's easy to see the opportunity to get confused between LGMD or, in that case, a metabolic myopathy or other acquired myopathies. And I think particularly adult neurologists are more accustomed to seeing acquired muscle disease. Are there particular clues that, or pearls that adult neurologists seeing patients with muscle disease can use to recognize when they should be thinking about LGMD given the diverse phenotype? Dr Liewluck: Yes. What I always tell the patient is that there are more than a hundred different types of muscle diseases, but we can easily divide into groups: acquired and genetic or hereditary. So, the acquired disease is when you encounter the patients who present with acute or subacute cause of the weakness, relatively rapidly progressive. But on the opposite, if you encounter the patient who present with a much more slowly progressive cause of weakness over several months or years, you may need to think about genetic disease of the muscle with also including limb-girdle muscular dystrophy. The detailed exam to be able to distinguish between each type of muscular dystrophy. For example, if proximal weakness, certainly limb girdle muscular dystrophy. If a patient has facial weakness, scapular winking, so you would think about facial scapular hematoma dystrophy. So, the slowly progressive cause of weakness, proximal pattern of weakness, CK elevation, should be the point when you think about LGMD. Dr Smith: So, I have a question about diagnostic evaluation. I had a meeting with one of my colleagues, Qihua Fan, who's a great peripheral nerve expert, who also does neuromuscular pathology. And we were talking about how the pathology field has changed so much over the last ten years, and we're doing obviously fewer muscle biopsies. Our way of diagnosing them has changed a lot with the evolution of genetic testing. What's your diagnostic approach? Do you go right to genetic testing? Do you do targeted testing based on phenotype? What words of wisdom do you have there? Dr Liewluck: Yes, so, I mean, being a muscle pathologist myself, it is fair to say that the utility of muscle biopsies when you encounter a patient with suspects that limb girdle muscular dystrophy have reduced over the year. For example, we used to have like fifteen, seventeen hundred muscle biopsies a year; now we do only thirteen hundred biopsies a year. Yes, as you pointed out, the first step in my practice if I suspect LGMD is to go with genetic testing. And I would prefer the last gene panel that not only include the LGMD, but also include all other genetic muscle disease as well as the conjunctive myopic syndrome, because the phenotype can be somehow difficult to distinguish in certain patients. Dr Smith: So, do you ever get a muscle biopsy, Teerin? I mean you obviously do; only thirteen hundred. Holy cow, that's a lot. So, let me reframe my question. When do you get a muscle biopsy in these patients? Dr Liewluck: Muscle biopsy still is present in LGMD patients, it's just we don't use it at the first-tier diagnostic test anymore. So, we typically do it in selected cases after the genetic testing in those that came back inconclusive. As you know, you may run into the variant of unknown significance. You may use the muscle biopsy to see, is there any histopathology or abnormal protein Western blot that may further support the heterogenicity of the VUS. So, we still do it, but it typically comes after genetic testing and only in the selected cases that have inconclusive results or negative genetic testing. Dr Smith: I'd like to ask a question regarding serologic testing for autoantibodies. I refer to a really great case in your article. There are several of them, but this is a patient, a FKRP patient, who was originally thought to have dermatomyositis based on a low-titer ME2 antibody. You guys figured out the correct diagnosis. We send a lot of antibody panels out. Wonder if you have any wisdom, pearls, pitfalls, for how to interpret antibody tests in patients with chronic myopathies? We send a lot of them. And that's the sort of population where we need to be thinking about limb-girdle muscular dystrophies. It's a great case for those, which I hope is everyone who read your article in detail. What do you have to say about that? Dr Liewluck: Yes, so myositis antibodies, we already revolutionized a few of muscle diseases. I recall when I finished my fellowship thirteen years ago, so we don't really have much muscle myositis antibodies to check. But now the panel is expanded. But again, the antibodies alone cannot lead to diagnosis. You need to go back to your clinical. You need to make sure the clinical antibodies findings are matched. For example, if the key that- if the myocytes specific antibodies present only at the low positive title, it's more often to be false positive. So, you need to look carefully back in the patient, the group of phenotypes, and when in doubt we need to do muscle biopsies. Now on the opposite end, the other group of the antibody is the one for necrotizing autoimmune myopathy; or, the other name, immune-mediated necrotizing myopathy. This is the new group that we have learned only just recently that some patients may present as a typical presentation. I mean, when even thinking about the whole testing autoimmune myopathy, we think about those that present with some acute rapidly progressive weakness, maybe has history of sudden exposures. But we have some patients that present with very slowly progressive weakness like muscular dystrophies. So now in my practice, if I encounter a patient I suspect LGMD, in addition to doing genetic testing for LGMD, I also test for necrotizing doing with myopathy antibodies at the same time. And we typically get antibody back within what, a week or two, but projected testing would take a few months. Dr Smith: Yeah. And I guess maybe you could talk a little bit about pitfalls and interpretation of genetic tests, right? I think you have another case in your article, and I've certainly seen this, where a patient is misdiagnosed as having a genetic myopathy, LGMD, based on, let's say, just a misinterpretation of the genetic testing, right? So, I think we need to think of it on both sides. And I like the fact that the clinical aspects of diagnosis really are first and foremost most important. But maybe you can talk about wisdom in terms of interpretation of the genetic panel?  Dr Liewluck:Yes. So genetic testing, I think, is a complex issue, particularly for interpretation. And if you're not familiar with this, it's probably best to have your colleagues in genetics that help looking at this together. So, I think the common scenario we encounter is that in those dystrophies that are autosomal recessive, so we expect that the patient needs to have two abnormal copies of the genes to cause the disease. And if patients have only one abnormal copy, they are just a carrier. And commonly we see patients refer to us as much as dystrophy is by having only one abnormal copy. If they are a carrier, they should not have the weakness from that gene abnormality. So, this would be the principle that we really need to adhere. And if you run into those cases, then maybe you need to broaden your differential diagnosis. Dr Smith: I want to go back to the clinical phenomenology, and I've got a admission to make to you, Teerin. And I find it really hard to keep track of these disorders at, you know, thirty-four and climbing a lot of overlap, and it's hard to remember them. And I'm glad that I'm now going to have a Continuum article I can go to and look at the really great tables to sort things out. I'm curious whether you have all these top of mind? Do you have to look at the table too? And how should people who are seeing these patients organize their thoughts about it? I mean, is it important that you memorize all thirty-four plus disorders? How can you group them? What's your overall approach to that? Dr Liewluck: I need to admit that I've not memorize all twenty-four different subtypes, but I think what I triy to do even in my real-life practice is group it all together if you can. For example, I think that the biggest group of these LGMD is what we call alpha-dystroglycanopathies. So, this include already ten different subtypes of recessive LGMD. So alpha-dystroglycan is the core of the dystrophin-associated glycoprotein complex. And it's heavy glycosylated protein. So, the effect in ten different genes can affect the glycosylation or the process of adding sugar chain to this alpha-dystroglycan. And they have similar features in terms of the phenotype. They present with proximal weakness, calf pseudohypertrophy, very high CK, some may have recurrent rhabdomyolysis, and cardiac and rhythmic involvement are very common. This is one major group. Now the second group is the limb-girdle muscular dystrophy due to defective membrane repair, which includes two subtypes is the different and on dopamine five. The common feature in this group is that the weakness can be asymmetric and despite proximal weakness, they can have calf atrophy. On muscle biopsy sometimes you can see a myeloid on the muscle tissues. And the third group is the sarcoglycanopathy, which includes four different subtypes, and the presentation can look like we share. For the rest, sometimes go back to the table. Dr Smith: Thank you for that. And it prompts another question that I always wonder about. Do you have any theories about why such variability in the muscle groups that are involved? I mean, you just brought up dystroglycanopathy, for instance, as something that can cause a very distal predominant myopathy; others do not. Do we at this point now have an understanding given the better genetics that we have on this and work going on in therapeutic development, which I want to get to in a minute, that provides any insight why certain muscle groups are more affected? Dr Liewluck: Very good question, Gordon. And I would say the first question that led me interested in muscle disease---and this happened probably back in 2000 when I just finished medical school---is why, why, why? Why does muscle disease tend to affect proximal muscles? I thought by now, twenty-five years later, we'd have the answer. I don't. I think this, you don't know clearly why muscle diseases, some affect proximal, some affect distal. But the hypothesis is, and probably my personal hypothesis is, that maybe certain proteins may express more in certain muscles and that may affect different phenotypes. But, I mean, dysferlin has very good examples that can confuse us because some patients present with distal weakness, some patients present with proximal weakness, that's by the same gene defect. And in this patient, when we look at the MRI in detail, actually the patterns of fatty replacements in muscle are the same. Even patient who present clinically as a proximal or distal weakness, the imaging studies show the same finding. Bottom line, we don't know. Dr Smith: Yeah, who knew it could be so complex? Teerin, you brought up a really great point that I wanted to ask about, which is muscle MRI scan, right? We're now seeing studies that are doing very broad MR imaging. Do you use some muscle MRI very frequently in your clinical evaluation of these patients? And if so, how? Dr Liewluck: Maybe I don't use it as much as I could, but the most common scenario I use in this setting is when I have the genetic testing come back with the VUS. So, we look at each VUS, each gene in detail. And if anything is suspicious, what I do typically go back to the literature to see if that gene defect in particular has any common pattern of muscle involvement on the MRI. And if there is, I use MRI as one of the two to try to see if I can escalate the pathogenicity of that VUS. Dr Smith: And a VUS is a “Variant of Unknown Significance,” for our listeners. I'm proud that I remember that as a geneticist. These are exciting times in neurology in general, but particularly in an inherited muscle disease. And we're seeing a lot of therapeutic development, a lot going on in Duchenne now. What's the latest in terms of disease-modifying therapeutics and gene therapies in LGMD? Dr Liewluck: Yes. So, there are several precritical and early-phase critical trials for gene therapy for the common lymphoma of muscular dystrophies. For example, the sarcoglycanopathies, and they also have some biochemical therapy that arepossible for the LGMD to FKRP. But there are many things that I expect probably will come into the picture broader or later phase of critical tryouts, and hopefully we have something to offer for the patients similar to patients with Duchenne muscular dystrophy. Dr Smith: What haven't we talked about, I mean, holy cow? There's so much in your article. What's one thing we haven't talked about that our listeners need to hear? Dr Liewluck: Good questions. So, I think we covered all, but often we get patients with proximal weakness and high CK, and they all got labeled as having limb-girdlemuscular dystrophy. What I want to stress is that proximal weakness and high CK is a common feature for muscle diseases, so they need to think broad, need to think about all possibilities. Particularly don't want to miss something treatable. Chronic, slowly progressive cause, as I mentioned earlier, we think more about muscle dystrophy, but at the cranial range, we know that rare patients with necrotic autonomyopathy and present with limb good of weakness at a slowly progressive cost. So, make sure you think about these two when suspecting that LGMD patient diabetic testing has come back inconclusive. Dr Smith: Well, that's very helpful. And fortunately, there's several other articles in this issue of Continuum that help people think through this issue more broadly. Teerin, you certainly don't disappoint. I enjoyed listening to you about a month ago, and I enjoyed reading your article a great deal and enjoy talking to you even more. Thank you very much. Dr Liewluck: Thank you very much, Gordon. Dr Smith: Again, today I've been interviewing Dr Teerin Liewluck about his article on limb-girdle muscular dystrophy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Please be sure to check out Continuum Audio episodes for this and other issues. And thanks to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Notes and Links to Anthony Gedell's Work       ANTHONY GEDELL writes from New Jersey publishing in Hobart, Poverty House, Variant, Revolution John, Punk Noir Magazine, and Bull. His debut novel, Love Lies in the Throes of Rhetoric, was released in October 2024. Buy Love Lies in the Throes of Rhetoric   Anthony's Instagram   Anthony's Writing for Hobart Pulp   Video Review for Love Lies in the Throes of Rhetoric   At about 1:40, Pete and Anthony talk about inspirations for the podcast At about 3:00, Anthony talks about how teaching informs his writing, and vice versa, with observations on  At about 5:20, Anthony talks about being a concerted listener and always being cognizant of “getting into the room” of wonderful writers and writing conversations At about Anthony talks about the ways in which he and the book's significance have evolved in the year since publication   At about 8:40, Anthony talks about ideas of “writing from comfortability" and  At about 9:40, Anthony responds to Pete's question about what texts have resonated with his students, which includes a major shout out for Eli Cranor At about 13:00, Anthony highlights Of Mice and Men as one example of “high intensity emotion” that moves/interests readers  At about 14:50, Anthony cites Marlon James saying that “the new American novel is the crime novel” and talks about the “writer as journalist” in discussing ideas of writing dystopian in a dystopian world and “writing towards genre”  At about 20:10, Pete and Anthony discuss ideas of the continuity of writers and writing over the centuries  At about 25:00, Anthony expands on ideas of nihilism in contemporary society  At about 31:00, Pete reads the Ecclesiastes, Ch 9, Verse 4, the introduction for Love Lies in the Throes of Rhetoric At about 32:20, Anthony responds to Pete's questions about the book's opening and significance for the rest of the book At about 35:00, Anthony talks about lessons and questions brought out in Biblical passages At about 36:00, Pete responds to Anthony's questions about how Anthony's novel is evocative of Catholic/catholic themes At about 39:30, Anthony shares moving connections in real-life and in the novel and ideas of misery and tragedy and compassion  At about 43:40, the two discuss the “snare” trope and how Eudora has been seen in two ways by a lot of readers, and Anthony shouts out Light Years by James Salter-its beautiful sentences and the possibility of Nedra in Salter's book as a “snare character” At about 48:50, The two connect meaningful scenes and quotes from the novel to memorable Scripture At about 49:50, Anthony responds to Pete's musings about the interesting “too young to feel this old” after Pete rambles about a writing project that “got away” At about 52:40, Anthony references Conrad in talking about nihilism and hopelessness, particularly with regard to Trasc and Eudora, the book's protagonists  At about 55:25, Pete compliments Anthony's use of “snappy dialogue” and asks Anthony about ideas of impotence, especially as seen with Trasc and Eudora At about 1:00:15, Anthony details particular scenes and reflects on some meanings that come from the portraits of masculinity  At about 1:04:30, Trasc and his sensitive nature is discussed, and Anthony talks about   At about 1:06:30, Anthony talks cryptically and profoundly on the writing process for his novel and quotes a memorable line from Salter's Light Years At about 1:09:30, Pete and Anthony stan Who's Afraid of Virginia Wolff? and talk about the play's “dialectical violence”   At about 1:12:00, Anthony reflects on his writing style and the place from which he writes and how boredom and “soccer dad” literature enervates  At about 1:14:50, a quote from the novel leads to the two dissecting David Foster Wallace's work and its significance, and some texts that are thought to be overly celebrated   At about 1:18:00, Anthony reflects on dystopia, worldbuilding, and “collective human behaviors” and how the physical atmosphere he creates can shadow feelings and characters' characteristics  At about 1:23:00, Anthony emphasizes the intentionality of the writing in the novel,  while at the same time allowing for the speculation that comes with the uncertain world and readers' experiences At about 1:24:40, the two reflect on Biblical connections to revelation and Revelation and dystopia and apocalypse  At about 1:26:40, Anthony responds to Pete's question about “The Court” and connection the Greek Chorus      You can now subscribe to the podcast on Apple Podcasts, and leave me a five-star review. You can also ask for the podcast by name using Alexa, and find the pod on Stitcher, Spotify, and on Amazon Music. Follow Pete on IG, where he is @chillsatwillpodcast, or on Twitter, where he is @chillsatwillpo1. You can watch other episodes on YouTube-watch and subscribe to The Chills at Will Podcast Channel. Please subscribe to both the YouTube Channel and the podcast while you're checking out this episode.       Pete is very excited to have one or two podcast episodes per month featured on the website of Chicago Review of Books. The audio will be posted, along with a written interview culled from the audio. His conversation with Hannah Pittard, a recent guest, is up at Chicago Review.     Sign up now for The Chills at Will Podcast Patreon: it can be found at patreon.com/chillsatwillpodcastpeterriehl      Check out the page that describes the benefits of a Patreon membership, including cool swag and bonus episodes. Thanks in advance for supporting Pete's one-man show, DIY podcast and extensive reading, research, editing, and promoting to keep this independent podcast pumping out high-quality content!    This month's Patreon bonus episode features an exploration of flawed characters, protagonists who are too real in their actions, and horror and noir as being where so much good and realistic writing takes place.    Pete has added a $1 a month tier for “Well-Wishers” and Cheerleaders of the Show.     This is a passion project, a DIY operation, and Pete would love for your help in promoting what he's convinced is a unique and spirited look at an often-ignored art form.    The intro song for The Chills at Will Podcast is “Wind Down” (Instrumental Version), and the other song played on this episode was “Hoops” (Instrumental)” by Matt Weidauer, and both songs are used through ArchesAudio.com.     Please tune in for Episode 304 with Erin Somers, a writer, reporter, and book critic based in the Hudson Valley. Her fiction, essays, and criticism have appeared in The New York Times Magazine, Esquire, Best American Short Stories, and elsewhere.      Her second novel, The Ten Year Affair, was named a most anticipated book by The New York Times, The Washington Post, Vulture, Bustle, LitHub, W Magazine, Orion, and Our Culture, and it will be published by Simon & Schuster on October 21, the date the episode airs.    Please go to ceasefiretoday.org, and/or https://act.uscpr.org/a/letaidin to call your congresspeople and demand an end to the forced famine and destruction of Gaza and the Gazan people.

Dave, Charlotte, and Zack have a very chaotic series of conversations about whatever this week. Want Avatar talk? It’s here! Want 25 minutes of Dave silently listening to Charlotte and Zack talk about D&D podcasts? You got it! Up Next: My Marvelous Year — 2012 pt. 6 Fantastic Four / FF #605-606 / 17-18 … […] The post My Marvelous Year 2012 Variant C: DC Movies/TV, the end of the Ultimate line, and our favorite RPG podcasts! appeared first on Comic Book Herald.

Dave forces Zack to weigh in on “Video Game Difficulty Discourse” irt Silksong, and Charlotte pitches “The French Method” of comic publishing. Up Next: My Marvelous Year — 2012 pt. 4 Avengers vs. X-Men #1 to #12 Read the tie-ins IF YOU DARE Uncanny X-Men #12-14 Added by Patreon backer Justin W. AvX tie-ins Wolverine […] The post My Marvelous Year 2012 Variant B: We solve comics publishing, and talk Silksong! appeared first on Comic Book Herald.

Zack (king of podcasts in 2050), Charlotte, and Dave chat about Eyes of Wakanda and have another “state of the MCU/DCU” talk. Also, some Predator and Alien talk! Up Next: My Marvelous Year — 2012 pt. 3 Carnage U.S.A. #1 to #5 Zeb Wells and Clayton Crain. Cool covers? Scarlet Spider #1 to #3 I […] The post My Marvelous Year 2012 Variant A: Eyes of Wakanda review! appeared first on Comic Book Herald.